Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Cerebrovascular accident? 232 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 232 reports of Cerebrovascular accident have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.4% of all adverse event reports for OCRELIZUMAB.

232
Reports of Cerebrovascular accident with OCRELIZUMAB
0.4%
of all OCRELIZUMAB reports
17
Deaths
136
Hospitalizations

How Dangerous Is Cerebrovascular accident From OCRELIZUMAB?

Of the 232 reports, 17 (7.3%) resulted in death, 136 (58.6%) required hospitalization, and 13 (5.6%) were considered life-threatening.

Is Cerebrovascular accident Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 232 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Cerebrovascular accident?

ROSIGLITAZONE (7,899) APIXABAN (7,237) RIVAROXABAN (4,111) ADALIMUMAB (2,756) LENALIDOMIDE (2,330) DABIGATRAN ETEXILATE (2,175) TESTOSTERONE (2,172) ASPIRIN (1,904) SACUBITRIL\VALSARTAN (1,864) INSULIN GLARGINE (1,805)

Which OCRELIZUMAB Alternatives Have Lower Cerebrovascular accident Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Cerebrovascular accident Reports All Drugs Causing Cerebrovascular accident OCRELIZUMAB Demographics